SCHEMBL13288676

SCHEMBL13288676

Bc1cnn2c(NCc3ccc(CNC(=O)c4ccccc4Cl)cc3)cc(-c3ccccc3C)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 5/20 0.49
▸ GSK3B P49841 3/20 0.45
▸ HPGD P15428 3/20 0.43
▸ CYP1A1 P04798 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ TP53 P04637 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ LMNA P02545 2/20 0.39
▸ PPARG P37231 1/20 0.39
▸ GPR39 O43194 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13288652 0.86 CDK2 (0.51) CDK2GSK3BHPGDCYP1A1ALDH1A1
SCHEMBL13288648 0.86 CDK2 (0.51) CDK2GSK3BHPGDALDH1A1KDM4E
SCHEMBL13288866 0.84 CDK2 (0.59) CDK2GSK3BMEN1NPC1RAB9A
SCHEMBL13288770 0.83 CDK2 (0.52) CDK2GSK3BHPGDCYP1A1POLB
SCHEMBL13288647 0.83 GSK3B (0.41) CDK2GSK3BHPGDALDH1A1USP2
SCHEMBL13288886 0.83 CDK2 (0.52) CDK2GSK3BHPGDCYP1A1ALDH1A1
SCHEMBL13288715 0.83 ALDH1A1 (0.51) CDK2GSK3BHPGDALDH1A1USP2
SCHEMBL13288668 0.83 CDK2 (0.55) CDK2GSK3BHPGDCYP1A1TSHR
SCHEMBL13288769 0.83 CDK2 (0.55) CDK2GSK3BHPGDCYP1A1MEN1
SCHEMBL13119457 0.82 CDK2 (0.73) CDK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback